for educational and safety purposes
Every compound in the sci-wiki that affects gaba; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
31 sourced · 89 reference
Selank is a synthetic peptide anxiolytic and nootropic derived from the immune peptide tuftsin, developed in Russia as a non-sedating, non-addictive alternative to conventional anti-anxiety drugs. It eases anxiety while supporting memory and attention, and animal research links these effects to modulation of GABA, serotonin, and brain-derived neurotrophic factor. Typically given as a nasal spray, it offers calm and cognitive support without the dependence or withdrawal associated with benzodiazepines.
Emoxypine, best known by its succinate salt Mexidol, is a Russian antioxidant and antihypoxant used widely across the former Soviet states for stroke, cerebrovascular disease, and stress-related conditions [1][2]. It combines free-radical scavenging with membrane-stabilizing and mitochondrial-energy support, and in randomized clinical work it improved recovery after ischemic stroke [1]. For those interested in antioxidant neuroprotection, emoxypine is a long-established and clinically deployed compound with a distinctive dual antioxidant and metabolic profile.
Magnesium N-Acetyl Taurinate is a magnesium salt where the mineral is paired with N-acetyltaurine, which is an acetylated (chemically capped) version of the amino acid taurine. The pitch behind it is delivery; the makers claim it is a more membrane-friendly form (one they say slips across cell membranes more easily) meant to carry both magnesium and its taurine partner across the blood-brain barrier (the tight filter that guards the brain) and into the central nervous system. Once inside, magnesium does its usual double job; it sits in the NMDA glutamate receptor like a natural gatekeeper that keeps that excitatory channel from firing too easily, and it works as a cofactor (helper molecule) for hundreds of enzymes. The taurine that is thought to be freed after the acetyl cap is cleaved (a release step that is not well characterized in people) is a calming neuromodulator (a molecule that gently tunes nerve signaling) that nudges GABA-A and glycine receptors and helps keep cellular calcium and water balance in check. People reach for it for stress, relaxation, sleep, and general cognitive support. Straight talk here; this is a newer, branded form and the human clinical evidence is early and thin, so most of the story is still mechanistic or preclinical rather than proven in large human trials.
Pregabalin (Lyrica) is a widely prescribed gabapentinoid that delivers fast, reliable relief from anxiety and nerve pain by calming overexcited neurons [1][3]. It binds the alpha-2-delta subunit of voltage-gated calcium channels, dialing down the release of excitatory neurotransmitters, a targeted mechanism that underlies its approved uses in generalized anxiety disorder, neuropathic pain, fibromyalgia, and epilepsy [1][6]. Valued for its rapid onset and predictable, linear pharmacokinetics, pregabalin is one of the most established calming agents in modern neurology and psychiatry [3][6].
Nefiracetam is a fat-soluble pyrrolidinone racetam that modulates cholinergic, glutamatergic, and calcium signaling. It potentiates neuronal nicotinic acetylcholine receptor currents at sub-nanomolar concentrations and enhances NMDA-receptor function and long-term potentiation through protein kinase C and CaMKII, giving it a pronounced pro-cognitive and neuroprotective profile in preclinical research; it has also been reported to reverse signaling deficits in a laboratory model of Rett syndrome. It has been studied for memory impairment, dementia, and post-stroke apathy and depression.
Fasoracetam is a racetam-class nootropic that acts on the glutamatergic and GABAergic systems; with repeated administration it up-regulates GABA-B and metabotropic glutamate (mGluR) receptors. It is one of relatively few racetams to have reached controlled human trials, having been evaluated in adolescents with attention-deficit hyperactivity disorder who carry variants in genes governing mGluR signaling. It remains an investigational compound and is not an approved medicine.
Phenibut (beta-phenyl-GABA) is a Russian-developed anxiolytic and nootropic prized for delivering calm, sociable focus and easier sleep [1][3]. Because an added phenyl ring lets it cross the blood-brain barrier that ordinary GABA cannot, it acts chiefly as a GABA-B receptor agonist, the target behind its reputation for melting away tension and quieting a racing mind [1][3]. Introduced into Soviet clinical practice in the 1960s, it remains one of the most recognizable GABAergic nootropics on the market, used for anxiety, stress, and relaxation [1][3].
Picamilon (N-nicotinoyl-GABA, pikamilon) is a Soviet-developed nootropic that fuses niacin with the calming neurotransmitter GABA into a single molecule, engineered to carry GABA across the blood-brain barrier that GABA alone cannot cross [4]. Introduced in Russia as a cerebrovascular agent, it is prized for combining gentle, non-sedating relaxation with improved blood flow to the brain [2][3]. Once inside the brain it is thought to split back into niacin, a vasodilator, and GABA, which quiets neural overactivity, an elegant two-in-one design that made it a mainstay of Russian neurology [2][4].
Apigenin is a naturally occurring flavone, a subclass of flavonoid plant pigment, found in many fruits, vegetables, and herbs, with especially high levels in chamomile, parsley, and celery. It is a yellow crystalline compound studied for antioxidant, anti-inflammatory, and mild calming effects, the last linked to its interaction with receptors in the brain. Apigenin is consumed as part of a normal diet and is also sold as a dietary supplement.
Ashwagandha is an adaptogenic herb prepared from the root of Withania somnifera, a small evergreen shrub in the nightshade family (Solanaceae) native to parts of Africa, the Middle East, and the Indian subcontinent. It has been used for centuries in Ayurveda, India's traditional system of medicine, as a rejuvenating tonic. Its main active constituents are steroidal lactones known as withanolides, and it is among the better-studied herbal supplements, with clinical research centering on stress, anxiety, and sleep.
Baclofen is a centrally acting skeletal muscle relaxant and agonist of the GABA-B receptor, used chiefly to relieve the muscle spasticity caused by conditions such as multiple sclerosis and spinal cord injury. Chemically it is a derivative of the inhibitory neurotransmitter GABA, modified to cross into the brain and spinal cord. It can be taken by mouth or, for severe spasticity, delivered directly into the spinal fluid by an implanted pump, and it is also used off-label for alcohol use disorder.
GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the mature mammalian central nervous system, where it lowers the excitability of nerve cells. The same molecule is sold as a dietary supplement marketed for relaxation, stress, and sleep. A long-standing point of debate is that orally taken GABA does not readily cross the blood-brain barrier, so how supplements produce their reported calming effects is not fully settled and may involve the peripheral nervous system and the gut rather than direct action in the brain.
Gabapentin is a prototypical gabapentinoid medicine used chiefly as an anticonvulsant and as a treatment for certain forms of nerve-related pain. Structurally it is a cyclic analogue of the inhibitory neurotransmitter GABA, yet despite its name it does not act directly on GABA receptors. First described in the mid-1970s and approved for medical use in the early 1990s, it is prescribed for focal seizures and for postherpetic neuralgia and is used off-label for a range of neuropathic and anxiety-related complaints.
Honokiol is a biphenolic neolignan found in the bark, seed cones, and leaves of magnolia trees. It is one of the main bioactive constituents of magnolia bark, a material long used in traditional Chinese and Japanese herbal medicine for anxiety and mood complaints. In laboratory and animal research honokiol has drawn interest for anxiolytic, anti-inflammatory, antioxidant, neuroprotective, and anti-tumor activities, though it remains a subject of preliminary study rather than an approved drug.
Hopantenic acid, best known by the Russian brand Pantogam and as its calcium salt calcium hopantenate, is a naturally occurring homologue of pantothenic acid in which the beta-alanine unit is replaced by GABA [1]. It is used in Russia and formerly in Japan as a gentle nootropic and mild anxiolytic-anticonvulsant, particularly in children with cognitive, behavioral and hyperkinetic problems [1][2]. Its effects are attributed to weak GABA-B-like modulation combined with support of neuronal metabolism, and the bulk of its clinical evidence is Russian rather than from large Western trials [1].
Kava is a beverage and herbal medicine prepared from the root of Piper methysticum, a shrub in the pepper family native to the islands of the Pacific. For centuries it has been consumed ceremonially and socially across Oceania for its calming, mildly intoxicating effects, and it is used more widely as a remedy for anxiety and tension [1][2]. Its activity comes from a group of compounds called kavalactones, and its safety, particularly concerning the liver, has been the subject of regulatory debate [3][4].
L-Theanine is a non-proteinogenic amino acid found almost exclusively in the tea plant Camellia sinensis, where it contributes part of brewed tea's savory taste. Chemically it is N-ethyl-L-glutamine, a structural analog of the neurotransmitter glutamate that crosses the blood-brain barrier and interacts with glutamate receptors, weakly modulating NMDA receptors and inhibiting binding at AMPA/kainate sites, while also raising dopamine and other monoamines; on EEG it increases alpha brain-wave activity, the signature of a relaxed but alert state. It is widely used as a supplement for relaxation, attention, and sleep, and is often paired with caffeine, with which it shows a well-studied synergy on attention, although the overall strength of the clinical evidence is still debated.
Lemon balm, known botanically as Melissa officinalis, is a lemon-scented perennial herb in the mint family, Lamiaceae. Native to the eastern Mediterranean and western Asia, it has been grown for over two thousand years and used traditionally to ease tension, lift mood, and aid digestion and sleep. Its leaves are rich in the polyphenol rosmarinic acid and in fragrant terpenes such as citronellal, geranial, and neral. Modern controlled studies have examined it for anxiety, mood, cognition, sleep, and palpitations, with its calming effect attributed largely to rosmarinic acid inhibiting GABA transaminase and to extract binding at cholinergic receptors.
Magnesium citrate is a magnesium salt of citric acid used both as a nutritional source of the mineral magnesium and as a saline osmotic laxative. Among magnesium supplements it is comparatively water-soluble and is generally considered to have good oral bioavailability relative to inorganic salts such as magnesium oxide [1][2]. Taken by mouth, it is used to relieve occasional constipation and to clear the bowel before procedures such as colonoscopy, and it appears in dietary supplements intended to help meet magnesium requirements.
Magnesium glycinate, also called magnesium bisglycinate or magnesium diglycinate, is a chelated compound in which the mineral magnesium is bound to two molecules of the amino acid glycine. It is used as a dietary supplement to raise or maintain magnesium status and is often chosen for being gentle on the digestive tract relative to some other magnesium salts [1][3]. Because it is a chelate, part of the compound appears to be absorbed as an intact magnesium-amino acid complex rather than solely as free magnesium ions [1].
Magnesium taurate is a compound pairing the mineral magnesium with the amino sulfonic acid taurine, promoted as a dietary supplement chiefly for cardiovascular and metabolic support. Interest in it originated largely from a 1996 hypothesis proposing that magnesium and taurine have complementary effects on blood vessels, blood pressure, and cellular calcium handling [1]. Direct human research on magnesium taurate itself is limited, and much of the supporting laboratory work has used the closely related salt magnesium acetyltaurate [2][3].
Magnolia bark is a herbal material obtained from the bark of Magnolia officinalis and related magnolia species, long used in traditional Chinese and Japanese medicine, where it is known as houpu or hou po. Its characteristic constituents are the polyphenolic lignans magnolol and honokiol, which are considered responsible for most of its biological activity [1][2]. Modern research has examined the bark and its isolated lignans for neuroprotective, anti-inflammatory, anti-anxiety, and antitumor properties, though most evidence comes from laboratory and animal studies rather than large human trials [1][2].
Passionflower usually refers to Passiflora incarnata, a climbing vine native to the southeastern United States and long used in herbal medicine. Its above-ground parts are taken, typically as teas, extracts, or tinctures, to ease anxiety and support sleep. It is thought to act on the brain's GABA system, and while some clinical studies suggest calming and sleep benefits, the overall evidence remains limited.
Pyridoxal-5-phosphate, often abbreviated PLP or P5P, is the biologically active coenzyme form of vitamin B6. It serves as an essential helper molecule for well over a hundred different enzymes, most of them involved in the metabolism of amino acids and the manufacture of neurotransmitters. The body makes PLP from the various dietary forms of vitamin B6, and it is also sold directly as a supplement marketed as a ready-to-use form of the vitamin.
Taurine is a sulfur-containing amino sulfonic acid, related to the amino acids but not used to build proteins, and it is especially abundant in the brain, heart, muscle, and retina. Beyond its familiar roles in bile-salt formation, osmoregulation, and antioxidant defense, cells use taurine to chemically modify mitochondrial transfer RNA, attaching it at the anticodon wobble position so that certain codons are read correctly; this was the first evidence that taurine is a building block of a biological macromolecule, and losing the modification is the molecular cause of the mitochondrial diseases MELAS and MERRF. Obtained in the diet mainly from meat and seafood, it is a common ingredient in energy drinks and dietary supplements and is studied for cardiovascular, metabolic, and aging-related effects.
L-THP (levo-tetrahydropalmatine) is a plant alkaloid from Corydalis and related herbs with a long history in traditional Chinese medicine for its calming, sedative, and pain-relieving properties. Modern research has clarified its mechanism as a dopamine receptor modulator, and it has been carried all the way into a human clinical study for cocaine use disorder, an unusually strong evidence base for a botanical compound. For those exploring natural approaches to relaxation, sleep, and discomfort, L-THP is a genuinely well-studied and intriguing choice.
Valerian is an herbal supplement prepared from the root and rhizome of Valeriana officinalis, a flowering plant native to Europe and Asia. It has a long history of traditional use as a sleep aid and mild sedative and remains one of the more widely used botanicals for insomnia and nervous tension. Clinical evidence for its effectiveness is mixed, and it is sold as a dietary supplement or, in some regions, as an approved traditional herbal medicine.
Vitamin B6 is a water-soluble essential nutrient that exists as several interconvertible forms; pyridoxine is the stable form used in most supplements and food fortification. In the body it is converted to pyridoxal-5-phosphate (PLP), the active coenzyme that drives well over a hundred distinct enzyme reactions, most of them in amino acid metabolism and in the synthesis of neurotransmitters such as serotonin, dopamine, and GABA. Because of that reach it is tied to mood, energy metabolism, and the clearing of homocysteine, and it is a first-line remedy for the nausea of early pregnancy and a popular one for premenstrual symptoms. It is cheap and generally safe, but chronic high doses are the one real catch, since they can cause a slowly reversible sensory nerve injury.
Pregnanolone (3α-hydroxy-5β-pregnan-20-one, also written 3α,5β-tetrahydroprogesterone) is an endogenous neurosteroid, meaning a steroid that acts rapidly on neuronal ion channels rather than through classical intracellular hormone receptors, formed as a reduced metabolite of progesterone. It is the 5β epimer of allopregnanolone and a potent positive allosteric modulator of the GABA-A receptor (the pentameric chloride channel that carries most fast inhibitory signalling in the brain), giving it sedative, anxiolytic, anticonvulsant and anaesthetic properties. Under the International Nonproprietary Name eltanolone it was developed in the 1990s as an intravenous general anaesthetic, formulated in a soybean-oil emulsion after earlier castor-oil-solubilised steroid anaesthetics proved allergenic; smooth induction and cardiovascular stability were offset by slow recovery and skin reactions, and it was never marketed. Its sulfate and synthetic glutamate esters are studied separately as use-dependent inhibitors of the NMDA receptor, an excitatory glutamate channel implicated in excitotoxicity and neuroprotection.
Sodium valproate is the sodium salt of valproic acid and one of the principal forms of the drug valproate, a widely used anticonvulsant and mood stabilizer. It is prescribed for several types of epilepsy, for the manic phase of bipolar disorder, and for the prevention of migraine. Valproate carries strong warnings because it can cause serious birth defects and developmental problems when taken during pregnancy.
Sodium valproate combined with valproic acid is the formulation known as valproate semisodium or divalproex sodium, sold chiefly under the brand name Depakote. It is a stable one-to-one complex of the two forms that dissociates in the gut to release the same active valproate ion. It is used as an anticonvulsant and mood stabilizer, most notably for the manic episodes of bipolar disorder, and is often chosen for its gentler effect on the stomach.
1,3-Butanediol is an alcohol-like compound the body metabolizes into beta-hydroxybutyrate, a ketone body and, more prominently, into a beta-hydroxybutyrate ketone, giving it a slow, alcohol-like depressant effect. It's used industrially and as a food-grade solvent, and it's sometimes taken in place of GHB-family drugs. Its slow onset makes dose stacking and overshoot a serious risk.
2-Arachidonoylglycerol (2-AG) is an endogenous cannabinoid (endocannabinoid) that serves as the principal full agonist of the CB1 and CB2 cannabinoid receptors in the mammalian body. A monoacylglycerol built from arachidonic acid esterified to glycerol, it was isolated from rat brain and canine gut in 1995 and is now regarded as the most abundant endocannabinoid in the central nervous system. Unlike a stored transmitter, 2-AG is synthesized on demand from membrane phospholipids by sn-1-diacylglycerol lipases (DAGL-alpha and DAGL-beta) in response to elevated intracellular calcium, then released to act as a retrograde messenger at synapses before being rapidly hydrolyzed back to arachidonic acid and glycerol by monoacylglycerol lipase (MAGL). Through this signaling it modulates synaptic plasticity, pain, appetite, mood, neuroinflammation, and immune and cardiovascular function, and it is a central node of the wider endocannabinoid system.
2M2B (2-methyl-2-butanol) is a tertiary alcohol with sedative, alcohol-like effects; because it's a tertiary alcohol it isn't metabolized into a toxic aldehyde, so it's said to lack the hangover of ethanol. It's considerably more potent than drinking alcohol by volume. Being a solvent-grade chemical with a narrow margin, dosing errors and depressant stacking are the main dangers.
4-Methylpregabalin is an investigational gabapentinoid (an alpha2delta calcium-channel ligand) and a close structural analog of pregabalin, carrying an additional methyl group at the 4-position of the aminomethyl-hexanoic-acid backbone (IUPAC 3-(aminomethyl)-4,5-dimethylhexanoic acid). Synthesized by Parke-Davis/Pfizer during structure-activity studies on the gabapentin and pregabalin scaffold, its active (3S,4S) stereoisomer binds the alpha2delta-1 auxiliary subunit of voltage-gated calcium channels with high affinity and produces anticonvulsant, analgesic and anxiolytic activity in preclinical models, in several of which it is reported to be more potent than pregabalin. It was never advanced to clinical trials or market and remains a research compound.
522-054 is a laboratory research compound built in Kelvin Gee's group at the University of California, Irvine to do two opposite things to the hippocampus at once: strengthen α7 nicotinic acetylcholine receptors and block the α5-subunit-containing GABA-A receptors that hold pyramidal cells under constant inhibition. In rats the combination potentiated synapses, lowered the threshold for long-term potentiation, and restored learning and attention that had been disrupted either by scopolamine or by a traumatic brain injury months earlier. The whole published record is two primary papers, both in rats and rat tissue, plus one review that summarises them. No human has been given it and no clinical trial exists.
Alfaxalone (also spelled alphaxalone) is a synthetic neuroactive steroid of the pregnane class that produces general anesthesia by acting as a positive allosteric modulator (a molecule that amplifies a receptor's response to its own neurotransmitter) at the GABA-A receptor, the principal inhibitory ion channel of the central nervous system. First introduced in 1971 as the main active component of the intravenous anesthetics Althesin (human) and Saffan (veterinary), it was withdrawn from human use in the 1980s because the solubilizing vehicle Cremophor EL provoked anaphylactoid reactions, then reintroduced in a cyclodextrin formulation marketed for veterinary anesthesia as Alfaxan. Because it lacks classical hormonal activity yet retains rapid, non-cumulative central depressant effects, alfaxalone occupies a distinct pharmacological niche among intravenous anesthetics and now serves as a template for a new generation of water-soluble neurosteroid sedatives such as Phaxan.
Allopregnanolone (chemically 3-alpha-hydroxy-5-alpha-pregnan-20-one, also known as 3-alpha,5-alpha-tetrahydroprogesterone or 3-alpha,5-alpha-THP) is an endogenous neurosteroid synthesized in the brain, adrenal glands and gonads as a downstream metabolite of the hormone progesterone. It is the prototypical inhibitory neuroactive steroid and one of the most potent known positive allosteric modulators (molecules that amplify a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), acting at both synaptic receptors and extrasynaptic delta-subunit-containing receptors. The pharmaceutical formulation of this exact molecule, brexanolone (trade name Zulresso), became in 2019 the first drug ever approved by the United States Food and Drug Administration specifically for postpartum depression, and its orally active analog zuranolone followed in 2023. Beyond its rapid actions on inhibitory neurotransmission, allopregnanolone participates in the stress response, ovarian-cycle and pregnancy physiology, seizure regulation and, as more recently characterized, the suppression of innate-immune inflammatory signaling.
Alpha-pinene is a bicyclic monoterpene and one of the most widely distributed terpene compounds in nature. It is a principal constituent of the resin and essential oils of conifers such as pine and spruce and is also present in rosemary, many culinary herbs, and cannabis, lending these plants their characteristic fresh, piney aroma. Alongside its role as a fragrance material and industrial feedstock, alpha-pinene has been studied for a range of biological activities, including anti-inflammatory, antimicrobial, and nervous-system effects [1][2].
Alprazolam (Xanax) is a fast, potent, short-acting benzodiazepine prescribed for anxiety and panic. Like all benzodiazepines it boosts the calming transmitter GABA; that makes it effective but also habit-forming, and its speed and potency give it a high misuse and dependence profile.
Amfecloral (INN; amphecloral USAN) is an obsolete mid-twentieth-century anorectic formed by condensing dextroamphetamine with chloral (trichloroacetaldehyde) to give a Schiff base, 2,2,2-trichloro-N-(1-phenylpropan-2-yl)ethanimine. It is effectively a dual-action prodrug: hydrolysis in the body regenerates dextroamphetamine, a monoamine-releasing central stimulant and appetite suppressant, together with chloral, whose reduction product trichloroethanol is a sedative-hypnotic that positively modulates GABA-A receptors [1][5]. The design intent was to pair an amphetamine 'up' with a GABAergic 'down' so that the sedative moiety would blunt the stimulant jitter while the anorectic effect persisted. Marketed briefly as Acutran, it was withdrawn in the early 1970s and is no longer a medicine.
AMN082 is the first identified selective allosteric agonist of the mGlu7 receptor, a group III metabotropic glutamate receptor that is the most abundant and evolutionarily conserved of the family and is concentrated at presynaptic terminals. It became the primary pharmacological tool for probing mGlu7 function in stress, anxiety, fear, addiction and depression. Because mGlu7 sits at active synaptic zones and requires high glutamate concentrations for physiological activation, an allosteric agonist offered a unique way to engage it directly. AMN082 is significant as the compound that opened experimental access to mGlu7 pharmacology, though its off-target effects require careful interpretation.
Androsterone (3α-hydroxy-5α-androstan-17-one) is an endogenous androstane neurosteroid (a steroid synthesized or acting within the nervous system) and a peripheral metabolite of testosterone and dehydroepiandrosterone. Like its pregnane counterpart allopregnanolone, it acts as a positive allosteric modulator (an agent that enhances a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory ion channel), producing barbiturate-like potentiation of inhibitory neurotransmission. In rodent studies it raises seizure threshold across multiple models and is regarded as an endogenous modulator of neuronal excitability; because native androsterone is rapidly conjugated and orally poorly available, a prodrug (an inactive precursor that converts to the active drug in the body) has been investigated for epilepsy.
Atagabalin (developmental code PD-0200390) is an investigational gabapentinoid, a conformationally constrained cyclopentane analogue of gabapentin that acts as a ligand at the alpha-2-delta (a2d) auxiliary subunit of voltage-gated calcium channels. It was developed by Pfizer primarily as a candidate hypnotic for insomnia, and was also examined for anxiety and neuropathic pain in the same mechanistic class as pregabalin and gabapentin. Like other a2d ligands it reduces the depolarization-evoked release of excitatory neurotransmitters rather than acting directly on GABA receptors, and in early trials it increased slow-wave sleep. Clinical development was ultimately discontinued after Phase II, and atagabalin has never been approved or marketed.
Baicalein is a naturally occurring flavone, a type of flavonoid, best known as one of the principal active compounds in the root of Baikal skullcap (Scutellaria baicalensis), a herb long used in traditional Chinese medicine. Chemically it is the aglycone of baicalin, meaning baicalin is its sugar-bearing form, and the two interconvert in the body. Laboratory and animal research has explored baicalein for antioxidant, anti-inflammatory, and neuroprotective effects, though it is not an approved medicine.
Baicalin is a flavonoid glucuronide, the sugar-bearing form of the flavone baicalein, and one of the most abundant active compounds in the root of Baikal skullcap (Scutellaria baicalensis). The root, called Huang Qin, is a staple of traditional Chinese medicine, and baicalin has been studied for anti-inflammatory, antioxidant, hepatoprotective, and anxiety-related effects. Despite a large body of laboratory work, its poor absorption and the shortage of large human trials keep it in the realm of research rather than approved medicine.
Bilobalide is a sesquiterpene trilactone, a plant compound found almost exclusively in the leaves of the ginkgo tree (Ginkgo biloba). It is one of the characteristic terpene trilactones that, together with the ginkgolides, define standardized ginkgo extracts [1]. In laboratory research it has drawn attention as a neuroprotective agent and as a negative modulator of GABA-A receptors, though its full range of actions in the brain is not completely understood [3][4]. It reaches people mainly as a minor constituent of ginkgo leaf supplements rather than as an isolated product.
Blue Lotus (Nymphaea caerulea) is a water lily used since ancient Egypt for its mild, dreamy, relaxing effects. Its activity is usually attributed to two alkaloids, apomorphine and nuciferine, which act on dopamine and other receptors. The effects are subtle; most people describe gentle relaxation, mild euphoria and enhanced dreaminess rather than a strong high.
Brivaracetam is a racetam-derivative antiseizure medication and an analog of levetiracetam, used as add-on therapy for focal, or partial-onset, seizures in people with epilepsy. It was rationally designed as a high-affinity, highly selective ligand of the synaptic vesicle glycoprotein SV2A, binding the target roughly 15 to 30 times more tightly than levetiracetam, and is associated in clinical use with a more favorable behavioral and psychiatric tolerability profile. Developed by the company UCB and marketed as Briviact, it received European and United States approval in 2016.
Bromazepam is a classic prescription benzodiazepine used mainly for anxiety. Like other benzodiazepines it calms the brain by enhancing the effect of GABA, the main inhibitory (calming) neurotransmitter, producing anxiety relief, sedation and muscle relaxation. It carries the usual benzodiazepine hazards: dependence with regular use, dangerous synergy with other depressants, and a rough withdrawal.
Chamomile is the common name for several daisy-like flowering plants in the family Asteraceae, most importantly German chamomile (Matricaria chamomilla, also cataloged as Matricaria recutita) and Roman chamomile (Chamaemelum nobile). Its dried flower heads have been used for centuries as a soothing herbal tea and folk remedy for relaxation, sleep, and digestion. The flowers are rich in the flavonoid apigenin and in terpenoids such as alpha-bisabolol and chamazulene, and modern research has documented anxiolytic, anti-inflammatory, and antioxidant activity, with the calming effect linked to apigenin binding the benzodiazepine site of the GABA-A receptor.
Clonazepam is a widely prescribed, long-acting benzodiazepine used for anxiety, panic and seizure disorders. It works by boosting GABA, the brain's main calming neurotransmitter, which produces sedation, anxiety relief and strong anticonvulsant effects. Its long duration makes it useful medically but also means it accumulates, and like all benzodiazepines it causes dependence and is dangerous with other depressants.
Clonazolam is a designer (research-chemical) benzodiazepine that is extremely potent, active in tiny amounts. It is a triazolo analog related to clonazepam and alprazolam and works the same way, enhancing GABA to produce heavy sedation and amnesia. Its sheer strength makes it very easy to overshoot and it is one of the more dangerous novel benzodiazepines.
Convolvulus pluricaulis is a small perennial herb of the morning glory family (Convolvulaceae), native to India and best known in Ayurvedic medicine as shankhpushpi [1][2]. It has long been used as a brain tonic to support memory and to calm the mind, and it is one of several plants traditionally sold under the shankhpushpi name [2][4]. Modern laboratory research has examined its extracts for memory-enhancing, anxiety-reducing and neuroprotective effects, although evidence in humans remains limited [2][3].
Deschloroetizolam is a designer thienodiazepine, the deschloro analog of etizolam (the same drug family, with a chlorine atom removed). It acts like a benzodiazepine, enhancing GABA to produce sedation, anxiety relief and amnesia. It is a research chemical with limited human data and, like other designer 'benzos', carries dependence, respiratory-depression and withdrawal risks.
Diclazepam is a designer benzodiazepine closely related to diazepam (Valium), essentially a chlorinated version of it. It enhances GABA at the GABA-A receptor to produce sedation, anxiety relief and muscle relaxation, and it is fairly long-acting. As a research chemical it has little human data but shares all the familiar benzodiazepine hazards of dependence, dangerous depressant synergy and hard withdrawal.
E-6801 is a potent serotonin 5-HT6 receptor agonist, characterized as a high-efficacy partial-to-full agonist depending on assay conditions, developed at Laboratorios Dr. Esteve. It is an imidazothiazole sulfonamide with very high potency at the receptor and has been used to demonstrate that 5-HT6 activation, not only blockade, can be pro-cognitive. Together with its analogue E-6837 it helped clarify how forskolin stimulation and constitutively active receptors reveal true agonist efficacy at 5-HT6. It is a research compound with no clinical development but is an influential probe of 5-HT6 agonist biology.
E-6837 is a selective, high-affinity serotonin 5-HT6 receptor ligand developed at Laboratorios Dr. Esteve that behaves as a partial agonist at the rat receptor and a full agonist at the constitutively active human receptor. Unlike the cognition-focused members of its class, E-6837 is best known for a metabolic action: in diet-induced obese rats, chronic dosing produced sustained hypophagia and weight loss with an improved metabolic profile. Its weight-loss efficacy exceeded that of the reference drug sibutramine while causing less rebound weight regain. It remains a preclinical compound illustrating the appetite-regulating role of central 5-HT6 signaling.
Ecklonia cava is an edible brown alga (seaweed) found in the coastal waters of East Asia, especially around Korea and Japan. It is a rich source of polyphenols called phlorotannins, including the marker compound dieckol, which have been studied for antioxidant, anti-inflammatory, and other biological activities. Extracts of the seaweed are used in foods, dietary supplements, and cosmetics.
Eglumegad (developmental code LY354740) is a potent, selective orthosteric agonist of group II metabotropic glutamate receptors (mGlu2 and mGlu3) developed by Eli Lilly as a novel anxiolytic. By activating presynaptic autoreceptors that restrain glutamate release, it produced robust anti-anxiety effects in animal models and, through its prodrug LY544344, showed efficacy in human generalized anxiety disorder and experimental panic. Development was halted after preclinical convulsion findings, but eglumegad remains a foundational tool compound for group II metabotropic glutamate pharmacology. It is historically important as one of the first metabotropic glutamate agonists to reach human anxiety trials.
EMD-386088 is a selective serotonin 5-HT6 receptor agonist, described in some assays as a partial agonist, that is used as a pharmacological tool to study the receptor's role in mood, anxiety and cognition. It is a tetrahydropyridinyl indole developed by Merck (EMD) and is one of the more widely used 5-HT6 agonists in behavioural neuroscience. In rodent studies it produces antidepressant-like and anxiolytic-like effects after both local hippocampal and systemic administration, with effects blocked by selective 5-HT6 antagonists, confirming target specificity. It has no clinical development but is a valuable probe of 5-HT6 agonist biology.
Etazolate (EHT-0202) is a fascinating triple-mechanism molecule: a 1970s pyrazolopyridine anxiolytic that ExonHit repurposed for Alzheimer's disease. In one compound it combines PDE4 inhibition, positive allosteric modulation of GABA-A receptors, and stimulation of alpha-secretase, which raises the neurotrophic, neuroprotective fragment sAPPalpha and steers amyloid precursor protein away from toxic amyloid. It is one of the few compounds in this class to have actually completed a placebo-controlled Phase 2 trial in Alzheimer's patients.
Etiracetam is a synthetic compound of the racetam family and a close relative of piracetam. It is a racemic mixture whose biologically active enantiomer, the S-form, is levetiracetam, a widely used antiseizure medication; investigation of levetiracetam's mechanism led to the identification of the synaptic vesicle glycoprotein SV2A as its molecular target and as a novel class of antiepileptic drug target. Etiracetam itself was investigated for effects on memory and against seizures but was not marketed, with development focusing instead on its purified active enantiomer.
Etizolam is a thienodiazepine, a close cousin of the benzodiazepines that acts the same way on GABA. Prescribed for anxiety in some countries and sold as a research chemical elsewhere, it is potent and short-to-medium acting, with the same dependence and depressant-combination risks as classic benzodiazepines.
F-Phenibut (fluorophenibut) is a fluorinated analog of phenibut, a GABA-B agonist used as an anxiolytic and sleep aid; it's presumed to share phenibut's mechanism and is reported to be more potent. It produces anxiety relief, sociability, and sedation. Its real danger is fast tolerance and a severe, protracted dependence with a withdrawal that can rival benzodiazepine withdrawal.
Fasedienol (developmental code PH94B; international nonproprietary name aloradine) is a synthetic steroidal compound of the "pherine" class, formulated as a low-dose intranasal spray for the acute, as-needed treatment of anxiety. It is chemically the synthetic 4,16-androstadien-3β-ol isomer (molecular formula C19H28O), structurally related to but deliberately distinct from the endogenous putative human pheromone 5,16-androstadienol. Unlike classical neurosteroids such as allopregnanolone, it is not appreciably absorbed into the systemic circulation and does not act by directly modulating central GABA-A receptors (the brain's main inhibitory ion channels); instead it activates peripheral chemosensory neurons in the nasal mucosa, generating afferent signals that reach the olfactory bulb and amygdala (the brain's fear and threat-processing hub). Developed by Pherin Pharmaceuticals and later licensed to VistaGen Therapeutics, it advanced through positive Phase 2 trials in social anxiety disorder but produced mixed results in the pivotal PALISADE Phase 3 program, and it has continued to be investigated for generalized anxiety disorder and post-traumatic stress disorder.
Fenobam is an imidazole small molecule originally developed in the 1970s as a non-benzodiazepine anxiolytic whose mechanism was unknown until it was later identified as a selective mGlu5 negative allosteric modulator. This retrospective mechanistic discovery made fenobam an early prototype for mGlu5-based anxiolytics and a candidate for fragile X syndrome. A pilot single-dose trial in adults with fragile X syndrome reported no significant adverse effects and improvements in prepulse inhibition, a marker of sensory gating, in half of the participants. Fenobam holds historical importance as the first clinically studied mGlu5 negative allosteric modulator in humans.
Flualprazolam is a designer benzodiazepine, a fluorinated analog of alprazolam (Xanax) that is more potent than its parent. It is a triazolo benzodiazepine that enhances GABA to produce heavy sedation, anxiety relief and amnesia. It has appeared frequently in counterfeit pills and overdose reports, and its high potency makes it one of the more dangerous novel benzodiazepines.
Flubromazepam is a designer benzodiazepine notable for an extremely long duration; a single dose can produce effects and residual impairment lasting into multiple days. It enhances GABA at the GABA-A receptor for sedation, anxiety relief and muscle relaxation. Its very long half-life makes accumulation and next-day impairment a particular hazard, on top of the usual benzodiazepine risks.
Flubromazolam is a designer benzodiazepine and one of the most potent known, active in extraordinarily small amounts. It is a triazolo compound that enhances GABA to produce very heavy sedation, amnesia and, at higher doses, prolonged unconsciousness. Its combination of extreme potency and long duration makes it exceptionally dangerous and it has been linked to serious poisonings.
Flunitrazepam (brand name Rohypnol) is a potent prescription benzodiazepine used in some countries for severe insomnia and as a pre-anesthetic. It enhances GABA at the GABA-A receptor to produce strong sedation, muscle relaxation and marked amnesia. It is best known for its notoriety in drug-facilitated assault, a direct consequence of its strong sedative and memory-blocking effects.
Flunitrazolam is a designer benzodiazepine, a triazolo analog of flunitrazepam (Rohypnol) that is extremely potent, active in tiny amounts. It enhances GABA at the GABA-A receptor to produce heavy sedation and dense amnesia. Combining the potency of a triazolo ring with flunitrazepam's strong amnestic character makes it one of the more hazardous novel benzodiazepines.
Gabapentin enacarbil is an extended-release prodrug of the gabapentinoid gabapentin that is enzymatically hydrolyzed to gabapentin after absorption. It was engineered to overcome the erratic, saturable absorption of oral gabapentin by acting as a substrate for high-capacity nutrient transporters (MCT-1 and SMVT) expressed throughout the small and large intestine, yielding sustained, dose-proportional plasma gabapentin concentrations. Marketed as Horizant in the United States and Regnite in Japan, it is approved for moderate-to-severe primary restless legs syndrome (RLS, also called Willis-Ekbom disease) and for the management of postherpetic neuralgia. Like gabapentin, its active moiety binds the alpha-2-delta (a2d) auxiliary subunit of voltage-gated calcium channels rather than acting directly on GABA receptors, reducing depolarization-evoked release of excitatory neurotransmitters.
Galanin(1-15) is an active N-terminal fragment of galanin that behaves as a distinct signaling entity through galanin receptor 1 and receptor 2 heteroreceptor complexes. On its own it produces strong anxiogenic and depression-like effects in rodents, often exceeding those of full-length galanin, yet paradoxically it enhances the antidepressant action of fluoxetine and can reverse fluoxetine-induced memory impairment. These effects depend on GalR1-GalR2 complexes interacting with serotonin 5-HT1A receptors in the raphe, hippocampus, and prefrontal cortex. It is a preclinical fragment of interest as both a mood modulator and an adjunct concept for antidepressant therapy.
Galmic is a macrocyclic nonpeptide galanin receptor agonist built on a rigid protein-surface-mimicking scaffold that displays galnon's pharmacophores in a fixed spatial arrangement. It has micromolar affinity for GalR1 and essentially no affinity for GalR2, and after systemic administration it blocks seizures, produces antidepressant-like effects, and reduces inflammatory pain behavior in rodents. Galmic is a preclinical chemical tool that helped establish that galanin receptors can be engaged by drug-like macrocycles. It has not advanced to human studies.
Galnon is a low-molecular-weight, systemically active nonpeptide galanin receptor agonist and one of the first small molecules shown to activate galanin receptors in vivo. It was designed from the known pharmacophores of galanin and displaces radiolabeled galanin from brain membranes with micromolar affinity while inhibiting adenylate cyclase, consistent with agonist action. In rodents it is anticonvulsant, anxiolytic, and modulates reward circuitry, making it a foundational pharmacological tool for probing the galaninergic system. Galnon remains a preclinical research compound with no human development.
Ganaxolone (research code CCD-1042; brand name Ztalmy) is a synthetic neuroactive steroid, specifically the 3-beta-methyl analog of the endogenous neurosteroid allopregnanolone (a metabolite of progesterone). It is a positive allosteric modulator (a molecule that amplifies a receptor's response to its natural activator) of the GABA-A receptor, the brain's principal inhibitory chloride channel, and it enhances both synaptic (phasic) and extrasynaptic (tonic) inhibition, with particularly strong activity at delta-subunit-containing receptors. In March 2022 it became the first medicine approved by the United States Food and Drug Administration for seizures associated with CDKL5 deficiency disorder (a rare genetic developmental and epileptic encephalopathy caused by mutations in the cyclin-dependent kinase-like 5 gene), and the first synthetic neurosteroid approved as an anticonvulsant. The defining 3-beta-methyl group makes ganaxolone orally bioavailable, metabolically stable, and non-hormonal, distinguishing it from its parent neurosteroid, which requires intravenous administration.
GBL (gamma-butyrolactone) is an industrial solvent and a prodrug for GHB; once swallowed the body rapidly converts it to GHB, so it produces the same euphoria, disinhibition, and sedation. It's oily, extremely potent by volume, and absorbed faster than GHB itself. The overdose margin is frighteningly narrow, and mixing with alcohol is a well-known cause of death.
HU-210 is a synthetic cannabinoid that acts as an ultra-potent full agonist at both the CB1 and CB2 cannabinoid receptors. It is the (6aR,10aR) enantiomer of the 1,1-dimethylheptyl homolog of 11-hydroxy-delta-8-tetrahydrocannabinol, developed in the 1980s by Raphael Mechoulam's group at the Hebrew University of Jerusalem (the source of the "HU" prefix). Structurally a close analog of THC, HU-210 is estimated to be roughly 100 to 800 times more potent than delta-9-THC, with sub-nanomolar affinity at CB1 and a notably long duration of action. It has been used primarily as a pharmacological tool compound to probe the endocannabinoid system in preclinical models, and has also appeared as an adulterant in illicit "herbal incense" (Spice/K2) products. HU-210 is controlled as a Schedule I substance in the United States and is not an approved medicine.
Idalopirdine is a potent, selective serotonin 5-HT6 receptor antagonist developed by H. Lundbeck (as Lu AE58054) as an adjunctive symptomatic treatment for Alzheimer's disease. By blocking 5-HT6 receptors, which are expressed almost exclusively in the central nervous system and concentrated in the hippocampus and cortex, it disinhibits cholinergic, glutamatergic and monoaminergic transmission relevant to memory. A phase 2 trial (LADDER) in donepezil-treated moderate Alzheimer's disease showed a significant cognitive benefit, but the larger phase 3 STARSHINE, STARBEAM and STARBRIGHT programme failed to replicate it. Idalopirdine is discontinued for cognition and is now referenced primarily as a pharmacological tool and cautionary case study.
Imidazenil is an experimental imidazobenzodiazepine that acts as a partial agonist at the benzodiazepine site of GABA-A receptors. It was studied for anxiolytic and anticonvulsant activity that appears to come with far less sedation, memory impairment, and dependence than conventional benzodiazepines. The compound has never been developed into a marketed medicine and remains a laboratory research tool.
Intepirdine is a selective serotonin 5-HT6 receptor antagonist originally discovered at GlaxoSmithKline as SB-742457 and later licensed to Axovant Sciences as RVT-101 for Alzheimer's disease and dementia with Lewy bodies. Like other compounds in its class it was intended to enhance cognition by disinhibiting cholinergic and glutamatergic signaling in cortex and hippocampus. A phase 2 study suggested a modest global and cognitive benefit, but the pivotal phase 3 MINDSET trial in mild-to-moderate Alzheimer's disease was clearly negative. Its high-profile failure in 2017 effectively ended enthusiasm for 5-HT6 antagonism as a standalone dementia strategy.
Jujube is the common name for Ziziphus jujuba, a small thorny tree or shrub of the buckthorn family, Rhamnaceae, and for its edible fruit. Also called red date or Chinese date, it has been cultivated in China and neighboring regions for thousands of years, and the fruit is eaten fresh, dried, or candied as well as used in traditional medicine [1]. Its fruit and seeds contain saponins, flavonoids, and polysaccharides that are the focus of pharmacological study [1][2].
Lavender is a group of aromatic flowering plants of the genus Lavandula in the mint family, best known for the fragrant essential oil distilled from the flowers of species such as Lavandula angustifolia. Native to the Mediterranean region, it has a long history in perfumery, cooking, and traditional medicine, where it has been used to calm the mind and aid sleep. Its oil, rich in the compounds linalool and linalyl acetate, is used in aromatherapy and, in a standardized oral form, has been studied as a treatment for anxiety.
Linalool is a naturally occurring terpene alcohol found in the essential oils of lavender, coriander, and hundreds of other aromatic plants. A colorless, fragrant liquid, it is one of the most widely used scent ingredients in perfumes, soaps, and household products, and it also serves as a food flavoring. It has been studied for calming, anxiety-reducing effects when inhaled.
Lorazepam (brand name Ativan) is a widely used prescription benzodiazepine for anxiety, sedation, seizures and alcohol withdrawal. It enhances GABA, the brain's main calming neurotransmitter, to produce anxiety relief, sedation and muscle relaxation. It is intermediate-acting and, unlike many benzodiazepines, has no active metabolites, but it carries the same dependence and depressant-synergy risks as the rest of its class.
Magnesium is an essential dietary mineral and the second most abundant positively charged ion inside human cells. It serves as a cofactor for hundreds of enzymes, is required for every reaction that uses ATP, and is central to nerve conduction, muscle contraction, and heart rhythm. Low magnesium status has been linked to several chronic diseases, and magnesium is widely used both as a nutritional supplement and as a medicine.
Masupirdine is a potent, selective serotonin 5-HT6 receptor antagonist developed by Suven Life Sciences as SUVN-502 for cognitive deficits in Alzheimer's disease. It was distinctive as the first compound in its class tested on a background of both donepezil and memantine, reflecting real-world moderate Alzheimer's disease management. The pivotal phase 2 proof-of-concept study did not meet its prespecified cognitive endpoint, although exploratory post hoc analyses suggested that concurrent memantine may have masked a benefit. Suven has since pivoted masupirdine toward agitation in dementia rather than core cognition.
Mephenaqualone is a quinazolinone sedative-hypnotic, a close structural analog of methaqualone (the Quaalude drug). It is presumed to share methaqualone's mechanism, calming the brain by enhancing GABA, the main inhibitory neurotransmitter, to produce sedation and muscle relaxation. It is an obscure compound with little human data, and like all CNS depressants it is dangerous combined with other depressants.
Methaqualone (sold historically as Quaalude and Mandrax) is a sedative-hypnotic depressant that was once widely prescribed for sleep and anxiety before being pulled for heavy misuse. It calms the brain mainly by boosting GABA, the main inhibitory (calming) neurotransmitter, giving sedation, muscle relaxation and a disinhibited, drunk-like high. Like other CNS depressants it is dangerous with alcohol and opioids and can lead to dependence.
Metizolam is a thienodiazepine (a benzodiazepine-type molecule where one benzene ring is swapped for a thiophene ring) sold as a research chemical. It's the desmethyl analog of etizolam, so it's presumed to work the same way; by boosting GABA it produces sedation, muscle relaxation, and anxiety relief. Like all designer benzos, the real risk here is respiratory depression when mixed with other downers, plus a fast slide into dependence.
Midazolam is a short-acting benzodiazepine used medically for procedural sedation, anesthesia induction, and stopping active seizures. It's water-soluble, works fast, and clears quickly, which is why hospitals reach for it. Its short action doesn't make it safe to play with; it's a potent respiratory depressant, especially combined with opioids or alcohol.
Muscimol is the isoxazole alkaloid that makes Amanita muscaria, the red-and-white fly agaric, psychoactive. It is not produced by the mushroom directly in quantity; the fresh tissue carries ibotenic acid, which loses carbon dioxide on drying, ageing or heating to give muscimol, so how a sample was handled changes what is in it [4]. Pharmacologically it is a potent and unusually selective agonist at ionotropic GABA-A receptors, the brain's main inhibitory channel, and it has been the reference compound that GABA-A pharmacology is written against for fifty years [1]. It is sold as a research chemical and used in neuroscience as a tool for silencing a brain region reversibly.
N-Acetyl Selank is an acetylated analog of Selank, a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro that is derived from the immune-modulating peptide tuftsin. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is used in Russia as an anxiolytic and nootropic, typically delivered as a nasal spray. The N-acetyl modification is intended to increase resistance to enzymatic breakdown; it has been studied far less than the parent peptide, and neither form is approved outside a small number of countries.
NAX 810-2 is a second-generation galanin analog engineered to prefer galanin receptor 2 over receptor 1, developed to preserve the anticonvulsant and analgesic benefits of galanin signaling while avoiding the hyperglycemia caused by GalR1-preferring predecessors. It has roughly fifteen-fold selectivity for GalR2, blocks seizures in multiple rodent models after intravenous dosing, and is analgesic across inflammatory and neuropathic pain assays. Crucially, it does not impair insulin secretion or raise growth hormone, giving it a cleaner metabolic profile than NAX-5055. It was framed as a first-in-class analgesic and antiseizure candidate.
NAX-5055, also known as Gal-B2, is a systemically active, metabolically stable galanin analog engineered to cross the blood-brain barrier by combining cationization with position-specific lipidization. It is a GalR1-preferring agonist with low-nanomolar receptor affinity and potent anticonvulsant activity in multiple rodent seizure models, including models of pharmacoresistant epilepsy. It was positioned as a potential first-in-class antiepileptic neuropeptide therapeutic. NAX-5055 also engages peripheral GalR1 to raise blood glucose, which shaped subsequent development toward GalR2-preferring successors.
nicotine is a genuinely nootropic nicotinic agonist with a small, real, meta-analysis-backed edge on attention and psychomotor speed (bigger in cholinergic-deficit brains than in healthy young ones), delivered through α4β2, α6 and α7 receptors; the honest catch is that it's an addictive drug whose habit-forming power scales with how fast you take it, so the entire case for using it rests on non-combusted low-dose delivery and clear eyes about dependence.
Nifoxipam is a designer benzodiazepine structurally related to flunitrazepam (Rohypnol); it's the 3-hydroxy desmethyl derivative and is presumed to share the same GABA-A mechanism. Sold as a research chemical, it's reported to be strongly sedative and hypnotic. As with the whole class, its main dangers are respiratory depression in combination with other depressants and rapid dependence.
Oleamide (cis-9,10-octadecenoamide) is an endogenous fatty acid primary amide, the simple amide of oleic acid, and the prototypical member of a family of brain lipids that function as biological signaling molecules [1]. It first drew attention when it was isolated from the cerebrospinal fluid of sleep-deprived cats, where it accumulates in proportion to the sleep debt and, when injected into rats, induces physiological sleep [1]. Mechanistically it is a substrate of fatty acid amide hydrolase (FAAH), the same enzyme that degrades the endocannabinoid anandamide, and it modulates cannabinoid, serotonergic, GABAergic, and gap-junction signaling [2][3][4][5]. In the supplement market it is sold as a sleep and relaxation aid, although controlled human evidence remains thin and most of what is known derives from cell and rodent work [6][13].
Pentobarbital is a short-to-intermediate-acting barbiturate historically used as a sedative, hypnotic, and anesthetic, and today for uses like refractory seizures, controlled coma, and veterinary euthanasia. Barbiturates have a notoriously narrow safety margin; the gap between a sedating dose and a lethal one is small. Combined with alcohol or opioids the overdose risk climbs sharply.
Phenelzine, sold as Nardil, is a classic irreversible, non-selective monoamine oxidase inhibitor (MAOI), an older but powerful antidepressant. What sets it apart from other MAOIs is a second action: it also inhibits GABA-transaminase, the enzyme that breaks down GABA, so it raises brain GABA levels, and it metabolizes to phenylethylidenehydrazine (PEH), the compound thought to drive much of that GABA effect. That extra, calming mechanism is a big part of why phenelzine is unusually effective for anxiety as well as depression; it also raises phenylethylamine (PEA), a natural trace amine.
Phenobarbital is a long-acting barbiturate still widely used as an anticonvulsant (seizure medication) and, historically, as a sedative. Its long duration makes it useful for steady seizure control and for managing withdrawal from other depressants. It shares the barbiturate hazards; a narrow safety margin and dangerous synergy with other central nervous system depressants.
Phenylethylidenehydrazine (PEH) is a metabolite of the antidepressant phenelzine and a research compound in its own right. Its main action is inhibition of GABA-transaminase (GABA-T), the enzyme that breaks down GABA, so it raises brain GABA levels; this GABA-boosting effect is thought to account for much of phenelzine's distinctive anti-anxiety character. It also influences phenylethylamine (PEA) metabolism. PEH is not a medicine you can be prescribed; it is studied mainly to tease apart which of phenelzine's effects come from raising GABA versus inhibiting monoamine oxidase.
Pyrazolam is a designer triazolobenzodiazepine (a benzodiazepine with a fused triazole ring, structurally akin to alprazolam) sold as a research chemical. It's noted for being fairly selectively anxiolytic (anxiety-reducing) with comparatively little sedation, and it resists metabolism into other active compounds. It still carries the class risks; dependence and dangerous synergy with other depressants.
Rosmarinic acid is a natural polyphenol, specifically an ester of caffeic acid, found in many culinary herbs. It is abundant in plants of the mint and borage families, including rosemary, lemon balm, sage, and basil, where it appears to serve as a defensive compound. Valued for its antioxidant and anti-inflammatory properties, it is used as a food flavoring and preservative, in cosmetics, and as a dietary supplement.
SB-271046 is one of the first potent and selective serotonin 5-HT6 receptor antagonists, developed at SmithKline Beecham as a research tool and early cognition-enhancer candidate. It is a benzothiophene sulfonamide with high 5-HT6 affinity and behaves as an antagonist or inverse agonist at the receptor. Widely used in preclinical neuroscience, it helped establish the link between 5-HT6 blockade and increased cortical glutamate and cognitive performance. It was never developed into a marketed drug and remains a benchmark reference antagonist for the receptor.
SB-399885 is a potent, selective and orally active serotonin 5-HT6 receptor antagonist developed at GlaxoSmithKline as a cognition-enhancer research compound. It has very high 5-HT6 affinity and more than 200-fold selectivity over other receptors, ion channels and enzymes, making it one of the cleaner pharmacological probes for the receptor. In rodent studies it reversed scopolamine- and dizocilpine-induced memory deficits, improved spatial learning in aged rats and raised cortical acetylcholine. It was never marketed but is a well-validated tool antagonist widely used to test the 5-HT6 cognition hypothesis.
Scutellaria, commonly called skullcap, is a large genus of flowering plants in the mint family (Lamiaceae), several species of which are used in herbal medicine. The two most important are Chinese, or Baikal, skullcap (Scutellaria baicalensis), whose root Huang Qin is a staple of traditional Chinese medicine, and American skullcap (Scutellaria lateriflora), traditionally used for anxiety and nervous conditions. Their effects are attributed largely to flavonoids such as baicalin, baicalein, and wogonin.
Secobarbital is a short-acting barbiturate that was once a common sleeping pill and sedative, sold under the name Seconal. Its rapid onset and short duration made it popular but also gave it high abuse potential and a bad overdose record. Like all barbiturates it has a narrow safety margin and is very dangerous with alcohol or opioids.
Sepranolone (isoallopregnanolone; 3beta-hydroxy-5alpha-pregnan-20-one) is an endogenous pregnane neurosteroid that is the 3beta-epimer of allopregnanolone, differing only in the spatial orientation of a single hydroxyl group at carbon 3. Whereas allopregnanolone is one of the most potent known positive modulators of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), isoallopregnanolone possesses no intrinsic modulatory activity of its own and instead acts as a selective functional antagonist that reverses allopregnanolone's enhancement of GABA-A signalling without touching the benzodiazepine site, the barbiturate site, or the basal GABA response. Under the development name UC1010 it has been advanced by Asarina Pharma as a subcutaneously administered candidate for premenstrual dysphoric disorder (PMDD) and related menstrually entrained and compulsive conditions, reaching Phase 2 clinical testing. It represents the prototype of a drug class termed GAMSA (GABA-A receptor modulating steroid antagonists).
SNAP-37889 is a potent, selective small-molecule antagonist of the galanin receptor 3 subtype, studied together with its more water-soluble analog SNAP-398299. In rodents both compounds produce anxiolytic and antidepressant-like effects, apparently by lifting galanin's inhibitory brake on serotonin transmission at the dorsal raphe nucleus. They were among the first brain-penetrant GAL3-selective tools and helped identify GAL3 as a candidate target for mood disorders. Both remain preclinical research compounds, limited in part by poor aqueous solubility.
Temazepam is a prescription benzodiazepine used mainly as a hypnotic (sleep aid) for short-term insomnia. It's an intermediate-acting agent that's a metabolite of diazepam, so it works through the standard GABA-A mechanism. Its risks are the usual class ones; dependence with continued use, and severe respiratory depression when combined with opioids or alcohol.
THDOC (3-alpha,5-alpha-tetrahydrodeoxycorticosterone) is an endogenous neurosteroid (a steroid that acts rapidly on neuronal membrane receptors rather than on classical nuclear hormone receptors) and the fully reduced 3-alpha,5-alpha metabolite of the adrenal steroid deoxycorticosterone. It is one of the most potent naturally occurring positive allosteric modulators (compounds that amplify a receptor's response to its own transmitter) of the GABA-A receptor, the brain's principal inhibitory chloride ion channel, where it enhances both fast synaptic and sustained extrasynaptic inhibition. Because its synthesis is driven by adrenocorticotropic hormone and by acute stress, THDOC is regarded as a stress-responsive inhibitory neurosteroid that provides negative feedback on the hypothalamic-pituitary-adrenal axis and transiently raises the seizure threshold. Alongside allopregnanolone, it is a prototypical member of the stress-derived GABAergic neurosteroid family.
WAY-181187 is a potent and selective serotonin 5-HT6 receptor agonist developed at Wyeth as a pharmacological tool to probe the receptor's biology. It is notable for illustrating the 5-HT6 paradox, in which receptor activation, not just blockade, can produce potentially beneficial central effects. In rodents it robustly increases extracellular GABA in cortex, hippocampus, striatum and amygdala, modestly lowers cortical dopamine and serotonin, and attenuates stimulated glutamate. It has shown anxiolytic-like and anticompulsive activity in animal models and is a standard reference agonist for the receptor.
WIN 55,212-2 is a synthetic aminoalkylindole cannabinoid receptor agonist that binds and fully activates both the CB1 and CB2 cannabinoid receptors, and is one of the most widely used reference agonists in endocannabinoid pharmacology. Developed by Sterling Winthrop from the aminoalkylindole (pravadoline) series while researchers were pursuing non-steroidal anti-inflammatory analgesics, it is structurally unrelated to plant-derived cannabinoids like THC yet produces overlapping in vivo effects including antinociception, hypothermia, catalepsy and hypomotility. It is a laboratory tool compound rather than an approved medicine, valued because it is a high-potency full agonist with slight CB2 preference and because its two enantiomers (the active R(+) form versus the near-inactive S(-) WIN 55,212-3) allow clean stereochemical control experiments. It has no approved medical use and is a Schedule I controlled substance in many jurisdictions as a synthetic cannabinoid.
Wogonin is a naturally occurring O-methylated flavone, chemically 5,7-dihydroxy-8-methoxyflavone, found chiefly in the root of Scutellaria baicalensis (Chinese skullcap). It is one of that plant's characteristic flavonoids and has drawn scientific interest as a positive allosteric modulator of the GABA-A receptor and for a range of preclinical anti-inflammatory and anticancer activities. Wogonin is a research compound rather than an approved medicine.
Zolpidem is the most prescribed sleeping pill in the world, sold as Ambien and Stilnox. It is not a benzodiazepine chemically, being an imidazopyridine unrelated to the cyclopyrrolones zopiclone and eszopiclone, but it acts at the same site on the same receptor. ⚠️ Its famous alpha-1 selectivity is about 375-fold over alpha-5 and alpha-6 but only sixfold over alpha-2 [1]. Its half-life of about two hours is roughly a third of eszopiclone's [4].
Zuranolone (development code SAGE-217; marketed as Zurzuvae) is an orally bioavailable synthetic analog of allopregnanolone (a naturally occurring neurosteroid derived from progesterone) that acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its own transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride channel). It was engineered by Sage Therapeutics from the same neurosteroid scaffold as the intravenous agent brexanolone, but with a modified 3-hydroxy pyrazole substitution that confers metabolic stability suitable for once-daily oral tablets rather than a continuous infusion. In August 2023 the United States Food and Drug Administration approved zuranolone for postpartum depression (a major depressive episode arising in the weeks after childbirth), making it the first oral drug indicated specifically for that condition. It is notable for producing an antidepressant response within days when given as a short, fixed two-week course, in contrast with the weeks-long onset of conventional monoamine antidepressants.
Zopiclone is a nonbenzodiazepine hypnotic of the cyclopyrrolone class, one of the Z-drugs, used for the short-term treatment of insomnia. Marketed under names such as Imovane and Zimovane, it was introduced in the 1980s and helps with both falling asleep and staying asleep. Although chemically unrelated to benzodiazepines, it acts on the same receptor site and carries similar risks of tolerance and dependence.
Eszopiclone is a sedative-hypnotic medication used to treat insomnia. It belongs to the nonbenzodiazepine group of sleep drugs often called Z-drugs, and chemically it is the active S-enantiomer of the older hypnotic zopiclone, in the cyclopyrrolone class. Marketed principally under the brand name Lunesta, it helps people fall asleep and stay asleep by enhancing the activity of the brain's main inhibitory neurotransmitter. It is a prescription medicine and, in the United States, a controlled substance.